Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Platinum resistance in breast and ovarian cancer cell lines Niels Eckstein | Journal of Experimental Clinical Cancer Research Eckstein Journal of Experimental Clinical Cancer Research 2011 30 91 http content 30 1 91 REVIEW Open Access Platinum resistance in breast and ovarian cancer cell lines Niels Eckstein Abstract Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15 and 6 respectively. Despite tremendous efforts to conquer malignant diseases the war on cancer declared by Richard Nixon four decades ago seems to be lost. Approximately 21 800 women in the US will be diagnosed with ovarian cancer in 2011. Therefore its incidence is relatively low compared to breast cancer with prognosed cases in 2011. However overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinumbased chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer. However in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the world are focussing on this issue. This review covers new findings in this field during the past decade. Introduction Among solid gynaecological tumors breast cancer is the most often diagnosed tumour while ovarian cancer is the most deadly gynaecological neoplasia. Cisplatin plays a completely different but important role in the treatment of both female cancer types. In ovarian cancer treatment Platinum-based chemotherapy plays a pivotal role as first line chemotherapy option and is usually combined with taxanes 1 . In breast cancer treatment cisplatin yet only is regarded a cytostatic reserve. According to current guidelines treatment of breast cancer normally is performed as chemotherapy triplets. The most commonly used cytostatics in the clinical management of the disease are Anthracyclines Cyclophosphamide Fluorouracil and Taxanes respectively. .
